Abstract: An anode for a lithium secondary battery includes an anode current collector, and a first anode active material layer and a second anode active material layer sequentially stacked on at least one surface of the anode current collector. The first anode active material layer and the second anode active material layer includes a first silicon-based active material and a second silicon-based active material, respectively.

Abstract: An anode active material for a secondary battery includes a carbon-based active material, and silicon-based active material particles doped with magnesium. At least some of the silicon-based active material particles include pores, and a volume ratio of pores having a diameter of 50 nm or less among the pores is 2% or less based on a total volume of the silicon-based active material particles.

Abstract: The technology and implementations disclosed in this patent document generally relate to a lithium secondary battery including: a first unit cell including a first anode including a 1-1 anode mixture layer and a 1-2 anode mixture layer on the 1-1 anode mixture layer, and a second unit cell including a second anode including a 2-1 anode mixture layer and a 2-2 anode mixture layer on the 2-1 anode mixture layer, wherein a weight ratio of the silicon-based active material in the 1-2 anode mixture layer is greater than a weight ratio of the silicon-based active material in the 1-1 anode mixture layer, and a weight ratio of the silicon-based active material in the 2-2 anode mixture layer is less than or equal to a weight ratio of the silicon-based active material in the 2-1 anode mixture layer.

Abstract: In some implementations, the anode includes a current collector, a first anode mixture layer formed on at least one surface of the current collector, and a second anode mixture layer formed on the first anode mixture layer. The first anode mixture layer and the second anode mixture layer include a carbon-based active material, respectively. The first anode mixture layer includes a first binder, a first silicon-based active material, and a first conductive material. The second anode mixture layer includes a second binder, a second silicon-based active material, and a second conductive material. Contents of the first conductive material and the second conductive material are different from each other with respect to the total combined weight of the first anode mixture layer and the second anode mixture layer. Types of the first silicon-based active material and the second silicon-based active material are different from each other.

Abstract: An anode for a lithium secondary battery includes an anode current collector, and an anode active material layer formed on at least one surface of the anode current collector. The anode active material layer includes a carbon-based active material, a first silicon-based active material doped with magnesium and a second silicon-based active material not doped with magnesium. A content of the first silicon-based active material is in a range from 2 wt % to 20 wt % based on a total weight of the anode active material layer.

Abstract: A compound selected from the group consisting of an isoquinoline-5-carboxamide derivative of formula (I), a pharmaceutically acceptable salt, an isomer, a hydrate and a solvate thereof is effective for the prevention or treatment of diseases associated with abnormal cell growth, which are caused by abnormal activation of a protein kinases.

Abstract: Disclosed is a method for the purification of bee venom on a mass scale. It comprises dissolving crude bee venom in a solvent to form a bee venom solution; applying an adsorbent to the bee venom solution to form a mixture; and removing the adsorbent through filtration to afford a pure bee venom solution. By the method of the present invention, crude bee venom collected from bee farms can be purified to a purity of 99% or higher on a mass scale, without inducing a change in the composition thereof, and thus the purified bee venom can be used as a material for medicines, cosmetics and foods.

Abstract: Provided are a thieno[3,2-d]pyrimidine derivative of formula (I) or a pharmaceutically acceptable salt thereof having inhibitory activity for protein kinase, and a pharmaceutical composition comprising same for prevention and treatment of abnormal cell growth diseases.

Abstract: A compound selected from the group consisting of an isoquinoline-5-carboxamide derivative of formula (I), a pharmaceutically acceptable salt, an isomer, a hydrate and a solvate thereof is effective for the prevention or treatment of diseases associated with abnormal cell growth, which are caused by abnormal activation of a protein kinases.

Abstract: Provided are a thieno[3,2-d]pyrimidine derivative of formula (I) or a pharmaceutically acceptable salt thereof having inhibitory activity for protein kinase, and a pharmaceutical composition comprising same for prevention and treatment of abnormal cell growth diseases.

Abstract: Disclosed is a method for the purification of bee venom on a mass scale. It comprises dissolving crude bee venom in a solvent to form a bee venom solution; applying an adsorbent to the bee venom solution to form a mixture; and removing the adsorbent through filtration to afford a pure bee venom solution.

Abstract: Provided is an artificial eardrum using silk protein and a method of fabricating the same. The artificial eardrum is fabricated in the form of a silk membrane by desalinating and drying silk protein (or silk fibroin) or a silk protein complex solution obtained after removal of sericin from a silkworm cocoon or silk fiber. Thus, regeneration of an eardrum perforated due to disease or a sudden accident is stimulated, a boundary of the regenerated eardrum is clean and biocompatibility and transparency are increased. In addition, the artificial eardrum may be fabricated using the silk protein or silk protein complex solution obtained from a silkworm cocoon alone or mixed with collagen, alginic acid, PEG or pluronic 127.

Abstract: The present invention relates to a composition for preventing and treating acne, comprising a material which has excellent antibacterial activity against Propionibacterium acnes known as acne-causing bacteria and which shows strong antibacterial activity against skin floras that enlarge the site of inflammation to worsen acne, in which the material also helps to regenerate skin cells damaged by acne. The composition comprises bee venom (collected from Apis meliffera) and is used the form of soap, cosmetic products, and medical products for skin application such as ointments, bands and dressings, which are used to fundamentally prevent and treat acne.

Abstract: Provided is an artificial eardrum using silk protein and a method of fabricating the same. The artificial eardrum is fabricated in the form of a silk membrane by desalinating and drying silk protein (or silk fibroin) or a silk protein complex solution obtained after removal of sericin from a silkworm cocoon or silk fiber. Thus, regeneration of an eardrum perforated due to disease or a sudden accident is stimulated, a boundary of the regenerated eardrum is clean and biocompatibility and transparency are increased. In addition, the artificial eardrum may be fabricated using the silk protein or silk protein complex solution obtained from a silkworm cocoon alone or mixed with collagen, alginic acid, PEG or pluronic 127.

Abstract: The present invention provides bee venom which can decrease expression levels of sclerotic factors, inflammatory factors and vascular adhesion factors associated with atherosclerosis, and a pharmaceutical composition comprising the bee venom as an active ingredient for the treatment of the atherosclerosis. When the bee venom was administered to laboratory animal models of atherosclerosis, the total cholesterol and neutral lipid were decreased, high-density cholesterol was maintained or even increased, the expression levels of TNF-? and IL-? as inflammation-associated cytokines were decreased in the blood, the expression levels of fibrosis-associated cytokines and vascular adhesion factors were decreased in the main artery and the heart, the plaque deposition generally caused by the atherosclerosis was decreased, and the expression levels of intercellular adhesion molecules (ICAM) and vascular cell adhesion molecules (VCAM), TGF-?1 and fibronectin as fibrosis-related cytokines were decreased.

Abstract: Provided are a thieno[3,2-d]pyrimidine derivative of formula (I) or a pharmaceutically acceptable salt thereof having inhibitory activity for protein kinase, and a pharmaceutical composition comprising same for prevention and treatment of abnormal cell growth diseases.